Stone Pharmaceutical Group intends not to exceed 120 million to obtain the right to commercialize the raw materials and tablets of ellotinib hydrochloric acid

Under the agreement, Shipharma will acquire the exclusive right (including full ownership and intellectual property rights) to commercialize and subsequently develop the product in China (excluding Hong Kong, Macau and Taiwan) and become a license holder for the product." As a result of the transfer, Shipharma agreed to pay Shanghai Chongno up to 120 million yuan in technology transfer milestone paymentsShipharma also agreed to pay a sales commission to Shanghai Chongno based on the product's sales in the region for a period of ten yearsthe ollotinib hydrochloric acid tablets are oral preparations to inhibit tumor cell proliferation by inhibiting the activity of HER-1/epidermal growth factor receptor (EGFR) on tumor cell ligand dependenceApproved indications are treatment for patients with late local or metastatic non-small cell lung cancer (NSCLC) whose EGFR gene has a sensitive mutation, including one-on-one treatment, maintenance treatment, or treatment of second-hand and above after at least one advance of chemotherapyThe elotinib hydrochloric acid is a category B category of medical insurance in the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalog.